Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone indicates disappointment and skepticism, as exemplified by statements like 'no activity' and expressions of hope dashed, such as 'Ugh, I was really hoping this would be positive.' The choice of blunt language and focus on negative results underscores a limited impact perception, even though the posts show high interest in the trial outcomes and basic understanding of the research context.
Most discussions express clear disappointment or skepticism regarding the limited effectiveness of erdafitinib in tumors with FGFR amplifications, indicating strong disagreement with positive expectations.
Posts demonstrate high interest by highlighting specific trial results, such as mentions of 'no activity' and detailed response rates, showing that the topic is highly relevant and engaging for the audience.
Despite high interest, the tone suggests a relatively shallow level of interaction, mainly summarizing results without delving into deeper analysis or implications, as seen in straightforward phrases like 'no activity' or 'informative but disappointing'.
The discussions reflect a perception that the study has limited practical impact due to its negative findings, suggesting that these results may influence future research directions but not immediate clinical practice.
2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in tumors w/#FGFR1-4 amplifications, informative that not all #FGFR alterations may be targetable https://t.co/HBd09KLaAT @OncoAlert @JCO_ASCO @ASCOPost https://t.co/7LooXN8p7g
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology @jgong15 https://t.co/a7C4fJ3wtx
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 | JCO Precision Oncology @jgong15 https://t.co/EPel7jNkgP
Ugh, I was really hoping this would be positive. Anyone have ideas on
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology https://t.co/U2lAIPOcvh
https://t.co/Yi4BdiNlJI
Dr Jun Gong discusses the limited activity of Erdafitinib in tumors with FGFR amplifications, mutations, or fusions based on recent phase II trial results. The study shows limited responses, with some stable disease…
DRUG TARGETS: in a pair of NCI-MATCH trials, FGFR inhibition (erdafitinib) was ineffective against cancers with FGFR1-4 amplifications (ORR 0%) but showed some efficacy against cancers with fusions or activating mutations (ORR 16%). https://t.co/y58I6y2FyS https://t.co/QuIcfPDqfJ
Ugh, I was really hoping this would be positive. Anyone have ideas on
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @DraMartinezLago: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Res…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
RT @DraMartinezLago: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Res…
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Result…
RT @VivekSubbiah: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Tri…
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology @jgong15 https://t.co/a7C4fJ3wtx
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 | JCO Precision Oncology @jgong15 https://t.co/EPel7jNkgP
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @DraMartinezLago: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Res…
RT @DraMartinezLago: https://t.co/Yi4BdiNlJI
https://t.co/Yi4BdiNlJI
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology https://t.co/U2lAIPOcvh
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
RT @jgong15: 2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in…
2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in tumors w/#FGFR1-4 amplifications, informative that not all #FGFR alterations may be targetable https://t.co/HBd09KLaAT @OncoAlert @JCO_ASCO @ASCOPost https://t.co/7LooXN8p7g